Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

Reza Ganji, Nastaran Majdinasab, Saeed Hesam, Nazanin Rostami, Mehdi Sayyah, Adeleh Sahebnasagh, Reza Ganji, Nastaran Majdinasab, Saeed Hesam, Nazanin Rostami, Mehdi Sayyah, Adeleh Sahebnasagh

Abstract

Background: Migraine is a painful and disabling nervous disorder which negatively affects the quality of life. Migraineurs may suffer from a generalized vasomotor dysfunction. Statins improve vasomotor and vascular function, with their pleiotropic effects. We aimed to assess efficacy and safety of adding Atorvastatin to prophylactic regimen in better control of migraine with aura.

Methods: This triple-blind controlled clinical trial was on 68 patients with migraine with aura. An interval of at least 1 month was given to evaluate vitamin D3 level and eligibility. In patients with vitamin D3 deficiency, the correction with vitamin D supplementation was provided. The patients were randomly assigned to receive atorvastatin 20 mg plus sodium valproate 500 mg or placebo plus sodium valproate 500 mg once a day for 2 months. The patients were evaluated based for the number of attacks and pain severity based on Visual Analogue Scale.

Results: There was a significant (p = 0.0001) improvement in severity of pain and number of migraine attacks by adding Atorvastin to the prophylactic regimen of patients with migraine with aura. After controlling for variable parameters, the differences between two arms of the study was yet statistically significant (p = 0.0001). A significant number of participants in intervention group were satisfied by their treatment (p = 0.001) with no remarkable side effects (P = 0.315).

Conclusions: Adding atorvastatin to migraine with aura preventive regimen may help reduce the number of acute attacks and pain severity without causing considerable side effects and led to a better patient satisfaction.

Trial registration: IRCT20180106038242N1 . Registered: 7 February 2018.

Keywords: Atorvastatin; Headache; Migraine with Aura; Prophylaxis; Sodium valproate.

Conflict of interest statement

The authors of present study declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow diagram of the study

References

    1. Hamedi V, Asghari A, Sheeri MR. An investigation of the effectiveness of a composed model of cognitive-behavior headache management on the treatment of anxiety, depression, stress and migraine symptoms. Procedia Soc Behav Sci. 2013;84:1850–1855. doi: 10.1016/j.sbspro.2013.07.046.
    1. Özturan A, Şanlıer N, Coşkun Ö. The relationship between migraine and nutrition. Turk Noroloji Dergisi. 2016;22(2):44-50.
    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache. 2001;41(7):646–657. doi: 10.1046/j.1526-4610.2001.041007646.x.
    1. Bahra A. Primary headache disorders: focus on migraine. Rev Pain. 2011;5(4):2–11. doi: 10.1177/204946371100500402.
    1. Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health. 2013;16(1):31–38. doi: 10.1016/j.jval.2012.08.2212.
    1. Boes CJ, Capobianco DJ, Cutrer FM, Dodick DW, Eross EJ, Swanson JW. Headache and other craniofacial pain. Neurol Clin Pract. 2008;2:2011–2062. doi: 10.1016/B978-0-7506-7525-3.50111-4.
    1. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976. doi: 10.1016/S1474-4422(18)30322-3.
    1. Benamer HT, Deleu D, Grosset D. Epidemiology of headache in Arab countries. J Headache Pain. 2010;11(1):1–3. doi: 10.1007/s10194-009-0173-8.
    1. Holroyd KA, Cottrell CK, O’Donnell FJ, Cordingley GE, Drew JB, Carlson BW, et al. Effect of preventive (β blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010;341:c4871. doi: 10.1136/bmj.c4871.
    1. Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist. 2006;12(4):204–213. doi: 10.1097/01.nrl.0000219666.65101.a9.
    1. Schankin CJ, Maniyar FH, Digre KB, Goadsby PJ. ‘Visual snow’–a disorder distinct from persistent migraine aura. Brain. 2014;137(5):1419–1428. doi: 10.1093/brain/awu050.
    1. Bigal ME, Lipton RB. The differential diagnosis of chronic daily headaches: an algorithm-based approach. J Headache Pain. 2007;8(5):263–272. doi: 10.1007/s10194-007-0418-3.
    1. Society HCCotIH The international classification of headache disorders, (beta version) Cephalalgia. 2013;33(9):629–808. doi: 10.1177/0333102413485658.
    1. Aghamohammadian HR, Kamal Shanbadi A. Effect of muscle relaxation and cognitive restructuring under hypnosis in women with migraine: single-case study. Iran J Psychiatry Behav Sci. 2007;13(2):182–188.
    1. Silberstein S, Diamond S, Loder E, Reed M, Lipton R. Prevalence of migraine sufferers who are candidates for preventive therapy: results from the American Migraine Prevalence and Prevention (AMPP) study OR11. Headache. 2005;45(6):770–771.
    1. Klapper J, obotDSiMPSG Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103–108. doi: 10.1046/j.1468-2982.1997.1702103.x.
    1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569–1582. doi: 10.1016/S0022-2275(20)41379-3.
    1. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang M-H, Tousoulis D, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124(3):335–345. doi: 10.1161/CIRCULATIONAHA.110.985150.
    1. Yanuck D, Mihos CG, Santana O. Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review. J Lipid Res. 2012;122(11):619–629.
    1. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77(2–3):247–253. doi: 10.1016/S0167-5273(00)00439-3.
    1. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21_suppl_1):II-18–II-26. doi: 10.1161/01.CIR.0000129505.34151.23.
    1. Zhou Q, Liao JK. Pleiotropic effects of statins. Circulation J. 2010;74(5):818–826. doi: 10.1253/circj.CJ-10-0110.
    1. Millar PJ, Floras JS. Statins and the autonomic nervous system. Clin Sci. 2014;126(6):401–415. doi: 10.1042/CS20130332.
    1. Ramachandran R, editor. Neurogenic inflammation and its role in migraine. In: Semin Immunopathol: Springer; 2018;40(3):301-14.
    1. Ceylan M, Bayraktutan OF, Becel S, Atis Ö, Yalcin A, Kotan D. Serum levels of pentraxin-3 and other inflammatory biomarkers in migraine: association with migraine characteristics. Cephalalgia. 2016;36(6):518–525. doi: 10.1177/0333102415598757.
    1. Palm-Meinders IH, Koppen H, Terwindt GM, Launer LJ, Konishi J, Moonen JM, et al. Structural brain changes in migraine. JAMA. 2012;308(18):1889–1896. doi: 10.1001/jama.2012.14276.
    1. Ghorbani Z, Togha M, Rafiee P, Ahmadi ZS, Magham RR, Djalali M, et al. Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial. Neurol Sci. 2020;41(5):1–10.
    1. Buettner C, Burstein R. Association of statin use and risk for severe headache or migraine by serum vitamin D status: a cross-sectional population-based study. Cephalalgia. 2015;35(9):757–766. doi: 10.1177/0333102414559733.
    1. Ghorbani Z, Togha M, Rafiee P, Ahmadi ZS, Magham RR, Haghighi S, et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurol Sci. 2019;40(12):1–19.
    1. Togha M, Razeghi Jahromi S, Ghorbani Z, Martami F, Seifishahpar M. Serum vitamin D status in a group of migraine patients compared with healthy controls: a case–control study. Headache. 2018;58(10):1530–1540. doi: 10.1111/head.13423.
    1. Kurata T, Deguchi K, Deguchi S, Ikeda Y, Abe K. Statins and reduction of oxidative stress in the aged brain. In: Diet and nutrition in dementia and cognitive decline: Elsevier; 2015. p. 753–60.
    1. Parsay S, Olfati F, Nahidi S. Therapeutic effects of vitamin E on cyclic mastalgia. Breast J. 2009;15(5):510–514. doi: 10.1111/j.1524-4741.2009.00768.x.
    1. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2017;2017(2):CD003225.
    1. Fan W, Lv Y, Ying G, Li W, Zhou J. Pilot study of amitriptyline in the prophylactic treatment of medication-overuse headache: a 1-year follow-up. Pain Med. 2014;15(10):1803–10. doi: 10.1111/pme.12517.
    1. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ. 2010;182(7):E269–EE76. doi: 10.1503/cmaj.081657.
    1. Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turhan H. Decreased endothelium-dependent vasodilatation in patients with migraine: a new aspect to vascular pathophysiology of migraine. Coron Artery Dis. 2006;17(1):29–33. doi: 10.1097/00019501-200602000-00005.
    1. Mason BN, Russo AF. Vascular contributions to migraine: time to revisit? Front Cell Neurosci. 2018;12:233. doi: 10.3389/fncel.2018.00233.
    1. Parsaik AK, Singh B, Hassan MM, Singh K, Mascarenhas SS, Williams MD, et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord. 2014;160:62–67. doi: 10.1016/j.jad.2013.11.026.
    1. Yin Z, Fang Y, Ren L, Wang X, Zhang A, Lin J, et al. Atorvastatin attenuates NF-κB activation in trigeminal nucleus caudalis in a rat model of migraine. Neurosci Lett. 2009;465(1):61–65. doi: 10.1016/j.neulet.2009.08.081.
    1. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-κB as a molecular target for migraine therapy. Ann Neurol. 2002;51(4):507–516. doi: 10.1002/ana.10159.
    1. Greco R, Tassorelli C, Cappelletti D, Sandrini G, Nappi G. Activation of the transcription factor NF-κB in the nucleus trigeminalis caudalis in an animal model of migraine. Neurotoxicology. 2005;26(5):795–800. doi: 10.1016/j.neuro.2005.02.005.
    1. Hesami O, Sistanizad M, Asadollahzade E, Johari M-S, Beladi-Moghadam N, Mazhabdar-Ghashghai H. Comparing the effects of atorvastatin with sodium valproate (divalproex) on frequency and intensity of frequent migraine headaches: a double-blind randomized controlled study. Clin Neuropharmacol. 2018;41(3):94–97. doi: 10.1097/WNF.0000000000000280.
    1. Liberopoulos EN, Mikhailidis DP. Could statins be useful in the treatment of patients with migraine? Headache. 2006;46(4):672–675. doi: 10.1111/j.1526-4610.2006.00293.x.
    1. Buettner C, Nir RR, Bertisch SM, Bernstein C, Schain A, Mittleman MA, et al. Simvastatin and vitamin D for migraine prevention: a randomized, controlled trial. Ann Neurol. 2015;78(6):970–981. doi: 10.1002/ana.24534.
    1. Pahan K, Sheikh FG, Namboodiri A, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. Clin Investig. 1997;100(11):2671–2679. doi: 10.1172/JCI119812.
    1. Giannopoulos S, Katsanos AH, Tsivgoulis G, Marshall RS. Statins and cerebral hemodynamics. J Cereb Blood Flow Metab. 2012;32(11):1973–1976. doi: 10.1038/jcbfm.2012.122.
    1. Potey C, Ouk T, Petrault O, Petrault M, Berezowski V, Salleron J, et al. Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia. Br J Pharmacol. 2015;172(21):5188–5198. doi: 10.1111/bph.13285.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner